Impact of Metabolic Syndrome on Development of Contrast Induced Nephropathy After Elective Percutaneous Coronary Intervention
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Ankara University
- Enrollment
- 599
- Locations
- 1
- Primary Endpoint
- Contrast induced nephropathy
Study Overview
Brief Summary
Prevention of contrast induced nephropathy after interventional cardiologic procedures deserves close interest because of its association with prolonged hospitalization, increased cost and increased in hospital and long term mortality rates. An observational prospective cohort study was designed to determine whether metabolic syndrome predicts the development of contrast induced nephropathy after elective percutaneous coronary intervention.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients must be scheduled for elective percutaneous coronary intervention Clinical diagnosis of metabolic syndrome Patients must give informed consent
Exclusion Criteria
- •Acute coronary events Acute renal failure End stage renal failure requiring hemodialysis Contrast allergy and exposure to nephrotoxic agent within 1 week before percutaneous coronary intervention Exposure to contrast agent within 1 week before the procedure.
Outcomes
Primary Outcomes
Contrast induced nephropathy
Time Frame: 24-48 hours after the percutaneous coronary intervention
Contrast induced nephropathy was defined as an increase in serum creatinine of \>25% or \>0.5 mg/dl above the baseline value 24 or 48 hours after angiography.
Secondary Outcomes
- glomerular filtration rate(48 hours after the percutaneous coronary intervention)
Investigators
Özgür Ulaş Özcan
MD
Ankara University
